Last reviewed · How we verify
NCT05422430
Rebreathing-induced Hypoxia and Glucose Levels
NA trial testing Rebreathing-induced hypoxia in Hypoxemia in 20 participants. Participants enrolled and being followed up; not accepting new ones.
4 September 2023
Quick facts
| Lead sponsor | University of Texas at Austin |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 21 October 2021 |
| Primary completion | 4 September 2023 |
| Estimated completion | 30 April 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Rebreathing-induced hypoxia
- Spontaneous breathing
Conditions studied
- Hypoxemia — all drugs for Hypoxemia →
Sponsor
University of Texas at Austin
Who can join
Adults 18 to 80, any sex, with Hypoxemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this research project is to determine the effect of repeated maximal voluntary apneas on glucose uptake during an oral glucose tolerance test in healthy individuals, individuals with prediabetes and patients with type 2 diabetes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05422430
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hypoxemia
Currently open trials in the same condition.
- NCT07451977 — Effects of Oxygen Supplementation During the 6-Minute Walk Test in Chronic Respiratory Failure or Exertional Hypoxemia · NA · recruiting
- NCT07234188 — POM vs HFNC for Hypoxemia Prevention in Children · NA · recruiting
- NCT07175155 — Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbi · NA · recruiting
- NCT07037836 — Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia · Phase 2 · recruiting
- NCT07517068 — The Role of Acetazolamide in Mitigating Inflammation and Innate Immune Activation at High Altitude · EARLY_PHASE1 · active not recruiting
Other University of Texas at Austin trials
Trials by the same sponsor.
- NCT07319234 — Development of MENU Protocol · NA · not yet recruiting
- NCT07480109 — Increased Dietary Protein Intake During GLP-1 Medication Use (in Middle-aged Women With Overweight/Obesity) · NA · not yet recruiting
- NCT07069413 — Sibwatch: Optimizing Intervention Options for Infants and Toddler Siblings of Autistic Children · NA · not yet recruiting
- NCT07370311 — A Culturally Adapted Decision Aid Intervention to Support Chinese American Dementia Caregivers in Feeding-Related Decisi · NA · not yet recruiting
- NCT07441122 — Enhancing Attention in Elderly Using a Brain-Computer-Interface · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05422430 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Texas at Austin
- Last refreshed: 25 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05422430.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing